A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. Litten, R. Z, Ryan, M. L, Fertig, J. B, Falk, D. E, Johnson, B., Dunn, K. E, Green, A. I, Pettinati, H. M, Ciraulo, D. A, Sarid-Segal, O., Kampman, K., Brunette, M. F, Strain, E. C, Tiouririne, N. A, Ransom, J., Scott, C., Stout, R., NCIG (National Institute on Alcohol Abuse, & Group, A. C. I. G. S. Journal of addiction medicine, 7(4):277--86.
A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. [link]Paper  doi  abstract   bibtex   
OBJECTIVES To assess the efficacy and safety of varenicline (Chantix) for the treatment of alcohol dependence. Varenicline is a partial $\alpha$4$\beta$2 nicotinic acetylcholine agonist approved by the Food and Drug Administration for smoking cessation. It has reduced drinking in animal studies and in small studies of humans who were both heavy drinkers and smokers. This is the first multisite clinical trial of varenicline in a population of smokers and nonsmokers with alcohol dependence. METHODS Men and women (n = 200) meeting the criteria for alcohol dependence were recruited across 5 clinical sites. Patients received double-blind varenicline or placebo and a computerized behavioral intervention. Varenicline was titrated during the first week to 2 mg/d, which was maintained during weeks 2 to 13. RESULTS The varenicline group had significantly lower weekly percent heavy drinking days (primary outcome) (adjusted mean difference = 10.4), drinks per day, drinks per drinking day, and alcohol craving compared with the placebo group (P \textless 0.05). The average treatment effect on alcohol use was similar for smokers and nonsmokers. Varenicline was well-tolerated; adverse events were expected and mild. CONCLUSIONS Varenicline significantly reduced alcohol consumption and craving, making it a potentially viable option for the treatment of alcohol dependence.
@article{Litten,
abstract = {OBJECTIVES To assess the efficacy and safety of varenicline (Chantix) for the treatment of alcohol dependence. Varenicline is a partial $\alpha$4$\beta$2 nicotinic acetylcholine agonist approved by the Food and Drug Administration for smoking cessation. It has reduced drinking in animal studies and in small studies of humans who were both heavy drinkers and smokers. This is the first multisite clinical trial of varenicline in a population of smokers and nonsmokers with alcohol dependence. METHODS Men and women (n = 200) meeting the criteria for alcohol dependence were recruited across 5 clinical sites. Patients received double-blind varenicline or placebo and a computerized behavioral intervention. Varenicline was titrated during the first week to 2 mg/d, which was maintained during weeks 2 to 13. RESULTS The varenicline group had significantly lower weekly percent heavy drinking days (primary outcome) (adjusted mean difference = 10.4), drinks per day, drinks per drinking day, and alcohol craving compared with the placebo group (P {\textless} 0.05). The average treatment effect on alcohol use was similar for smokers and nonsmokers. Varenicline was well-tolerated; adverse events were expected and mild. CONCLUSIONS Varenicline significantly reduced alcohol consumption and craving, making it a potentially viable option for the treatment of alcohol dependence.},
author = {Litten, Raye Z and Ryan, Megan L and Fertig, Joanne B and Falk, Daniel E and Johnson, Bankole and Dunn, Kelly E and Green, Alan I and Pettinati, Helen M and Ciraulo, Domenic A and Sarid-Segal, Ofra and Kampman, Kyle and Brunette, Mary F and Strain, Eric C and Tiouririne, Nassima A and Ransom, Janet and Scott, Charles and Stout, Robert and {NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group}},
doi = {10.1097/ADM.0b013e31829623f4},
file = {:Users/kdunn/Library/Application Support/Mendeley Desktop/Downloaded/Litten et al. - Unknown - A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence.pdf:pdf},
issn = {1932-0620},
journal = {Journal of addiction medicine},
number = {4},
pages = {277--86},
pmid = {23728065},
title = {{A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/23728065 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3914416},
volume = {7}
}

Downloads: 0